Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy

Acheampong, Desmond O.; Adokoh, Christian K.; Ampomah, Paulina; Agyirifo, Daniel S.; Dadzie, Isaac; Ackah, Francis A.; Asiamah, Ernest A.

dc.contributor.author	Acheampong, Desmond O.
dc.contributor.author	Adokoh, Christian K.
dc.contributor.author	Ampomah, Paulina
dc.contributor.author	Agyirifo, Daniel S.
dc.contributor.author	Dadzie, Isaac
dc.contributor.author	Ackah, Francis A.
dc.contributor.author	Asiamah, Ernest A.
dc.date.accessioned	2023-09-29T10:51:14Z
dc.date.available	2023-09-29T10:51:14Z
dc.date.issued	2017
dc.identifier.uri	http://hdl.handle.net/123456789/8688
dc.description.abstract	Abstract: Antibodies have become the preferred therapeutic treatment option for cancers. Antibody therapy is associated with low toxic profile and specific in its activity, unlike chemotherapy and ra- diotherapy. Types of tumor are known to express multiple receptors that cross-talk to activate per- petual growth, proliferation and metastasis, and inhibit apoptosis in such tumors. Bispecific antibod- ies (BsAbs) are therefore the preferred agent for the treatment of such cancers due to its unique char- acteristics. This review discusses up to date therapeutic potentials of BsAbs.	en_US
dc.language.iso	en	en_US
dc.publisher	University of Cape Coast	en_US
dc.subject	Antibody	en_US
dc.subject	bispecific antibody (BsAb),	en_US
dc.subject	immunotherapeutic agent	en_US
dc.subject	cancer therapy	en_US
dc.subject	diabody	en_US
dc.subject	antitumor	en_US
dc.title	Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy	en_US
dc.type	Article	en_US